Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The design of the study will be randomized, double blind trial, which will examine the
effects of Rosiglitazone on the fasting triglycerides (TG), high-density lipoprotein (HDL),
low-density lipoprotein (LDL), and plasma concentrations of apolipoproteins A-I, A-II, and
C-III as compared to Fenofibrate and placebo. This study will also assess the synergistic
effect of Rosiglitazone and Fenofibrate on the same parameters. Data from this study will
help clarify whether Rosiglitazone favorably impacts plasma lipid and lipoprotein
concentrations through improving insulin sensitivity and glycemic control, or by directly
influencing the synthesis of the apolipoproteins that are responsible for very-low-density
lipoprotein (VLDL) and HDL metabolism.